Alector, Inc. (ALEC) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of August 19, 2026. The Healthcare name (Biotechnology) last closed at $2.21. The rating moved from Neutral to Overbought on August 18, 2026.

• Public ratingOverbought (as of August 19, 2026)
• Last close$2.21
• Last changeMoved from Neutral to Overbought on August 18, 2026
• SectorHealthcare
• IndustryBiotechnology

See all overbought Healthcare stocks →

AI analysis

Alector, Inc. is a clinical-stage biotechnology company with upside tied to discrete program readouts and potential partnership or financing outcomes. Near-term performance will be driven by trial progress, cash runway, and any deal activity; market-friendly risk appetite can provide temporary support, but fundamental execution and funding are the primary determinants of direction. Given the company’s clinical-stage profile, investors should expect elevated volatility and event-driven price swings.

Key factors

• Pipeline exposure to neuroscience and immuno-modulatory programs provides upside from discrete clinical readouts or partnerships.
• Modest current market capitalization and low share price reflect high-risk / high-reward profile typical of clinical-stage biotechs.
• Liquidity and financing posture will materially influence near-term valuation; access to capital or partnerships could de-risk the balance sheet.
• Broader market tone is modestly risk-on, which can temporarily support speculative biotech names ahead of catalysts.
• Sector themes (biologics demand, CDMO tailwinds) are supportive for companies with biologic assets, though indirect for ALEC specifically.

Risks

• Clinical trial failures or negative readouts that materially reduce future revenue probability and valuation.
• High cash burn and potential need for dilutive financing if milestones or partnerships are delayed.
• Regulatory and reimbursement uncertainty for novel neuro-immune therapeutics.
• Competitive landscape with larger pharma players pursuing similar mechanisms or indications.
• Low trading liquidity and high volatility increasing downside in risk-off market moves.
• Execution risk around business development, trial timelines, and manufacturing scale-up.

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.